Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Metformin could be a treatment for women with pre-eclampsia
Thurs September 23rd - Metformin shows promise as a treatment for preterm pre-eclampsia, a study reveals today. More
AI identifies possible drug combination for brain cancer
Thurs September 23rd - Artificial intelligence-enhanced tools have been used to identify a new combination of drugs that could treat a rare and incurable childhood brain cancer. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Gene therapy programme launched for neurodegenerative diseases

Friday July 30th 2021

An innovative gene therapy programme has been launched that could lead to novel treatments for neurodegenerative diseases.

The research is being carried out by scientists at the University of Sheffield’s Institute for Translational Neuroscience (SITraN), with the Cell and Gene Therapy Catapult, after being awarded £513,141 from LifeArc and the Motor Neurone Disease (MND) Association.

The study will test the feasibility and efficiency of a gene therapy programme to treat motor neurone disease (MND) and frontotemporal dementia (FTD) patients with underlying mutations in the C9orf72 causative gene.

The researchers hope if it is successful, it could lead ground-breaking research into future clinical trials.

Dr Guillaume Hautbergue, head of the RNA Biology Laboratory, who is leading the study with Prof Mimoun Azzouz and Prof Dame Pamela Shaw, said: “This is a completely new approach to tackling the most common type of motor neurone disease.

“No one has yet attempted to prevent these repeated sequences of RNA from leaving the cell’s nucleus and it opens up new areas of investigation for gene therapy. It is an exciting time for biomedical research and the development of novel treatments for incurable diseases such as MND.”

In an early stage study, published in Nature Communications in 2017, Dr Hautbergue and his research team identified why the repeated RNA sequences can leave the cell’s nucleus to cause cell death.

They discovered the SRSF1 protein, which binds to the pathological repeated RNA molecules and transports them out of the cell centre, overrides the gatekeeping machinery within the nucleus by opening a back door.

They went on to show that reducing the SRSF1 protein or altering its makeup so that it is unable to interact with the cell’s export machinery can reduce the amount of rogue RNA molecules escaping into the cell’s cytoplasm.

Matthew Durdy, chief executive officer of the Cell and Gene Therapy Catapult, said: “The progress of this scientific breakthrough from the University of Sheffield and the support for this programme by leading investors and charities such as LifeArc and the MND Association, is testament to the UK research excellence and favourable ecosystem for cell and gene therapies.

“We welcome the opportunity to be part of this programme and look forward to working with the University of Sheffield to help advance their innovative gene therapy technology into the clinics.”

Dr Brian Dickie, director of research development at MND Association, added: “Gene therapy for neurodegenerative diseases, such as MND, has had its ups and downs over the past two decades, but the field is now enjoying a renaissance. There is a clear route to clinical trials if the outcomes of this new study are positive.”

Dr Melanie Lee CBE, chief executive officer of LifeArc, a self-funded medical research charity said: “This gene therapy approach, focused on preventing motor neurone toxicity, is the latest in a series of initiatives we are proud to be part of to drive research into practical treatments for this fatal and brutal condition.”

Tags: Brain & Neurology | Genetics | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)